{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:50Z","timestamp":1790916830695,"version":"4.1.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This article examines the role of aspirin in the primary prevention of cardiovascular disease. It highlights findings from major studies such as ASPREE (ASPirin in Reducing Events in the Elderly), ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events), and ASPREE-XT (ASPirin in Reducing Events in the Elderly - eXTension), among others. The review focuses on aspirin\u2019s role in primary prevention for specific populations including older adults, diabetics, hypertension patients, rheumatoid arthritis patients, kidney transplant recipients, and those with specific lipoprotein(a) genotypes, among other groups. We review these studies, noting aspirin\u2019s role in reducing events such as myocardial infarctions and its potential for increasing bleeding risks. The review also considers the implications for patients with kidney disease, referencing the Chronic Renal Insufficiency Cohort (CRIC) study and the International Polycap Study-3 (TIPS-3) trial. Additionally, it addresses the shifting paradigms in guidelines from the US Preventive Services Task Force and other entities, underscoring the importance of individualized aspirin use by balancing benefits against bleeding risks. The article further explores the concept of platelet reactivity, discusses strategies for improving adherence to aspirin therapy, and identifies existing research gaps, such as the phenomenon of aspirin resistance. It concludes by suggesting potential areas for future investigation to enhance understanding and application of aspirin in cardiovascular disease prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000000722","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T09:03:01Z","timestamp":1716541381000},"page":"541-554","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A Thorough Literature Review of the Potential Benefits and Drawbacks of Long-Term Aspirin Use for the Primary Prevention of Cardiovascular Disease"],"prefix":"10.1097","volume":"34","author":[{"given":"Abdalhakim R. M.","family":"Shubietah","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, An-Najah National University Hospital, Nablus, Palestine"},{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Pernia","family":"Marin","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Department, Columbia University, Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam M.","family":"Rajab","sequence":"additional","affiliation":[{"name":"Columbia University, Irving Medical Center, New York, NY,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd H.","family":"Oweidat","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hebron University, College of Medicine, Hebron, Palestine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Zayed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Hmeedan","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, An-Najah National University Hospital, Nablus, Palestine"},{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pcad.2019.07.001","article-title":"Atherosclerotic cardiovascular disease and heart failure: determinants of risk and outcomes in patients with diabetes.","volume":"62","author":"Nelson","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.14797\/mdcvj.293","article-title":"Aspirin in the modern era of cardiovascular disease prevention.","volume":"17","author":"Murphy","year":"2021","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2020.11.014","article-title":"Aspirin in primary prevention: what changed? A critical appraisal of current evidence.","volume":"141","author":"Dasa","year":"2021","journal-title":"Am J Cardiol"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3949\/ccjm.90a.22087","article-title":"Aspirin for primary prevention of cardiovascular disease: what do the current USPSTF guidelines say?","volume":"90","author":"Mallick","year":"2023","journal-title":"Cleve Clin J Med"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"100335","DOI":"10.1016\/j.ajpc.2022.100335","article-title":"Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology Clinical Practice statement.","volume":"10","author":"Wong","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"R7-20261002","article-title":"Strengths and limitations of the ASCVD risk score and what should go in the risk discussion.","author":"Lloyd-Jones","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0002-9343(00)00683-5","article-title":"Cyclooxygenase inhibition and thrombogenicity.","volume":"110","author":"Catella-Lawson","year":"2001","journal-title":"Am J Med"},{"key":"R10-20261002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","article-title":"Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention.","volume":"36","author":"Ornelas","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.5207","article-title":"Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement.","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00002018-199005050-00002","article-title":"Adverse reactions and interactions with aspirin considerations in the treatment of the elderly patient.","volume":"5","author":"Karsh","year":"1990","journal-title":"Drug Saf"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.2147\/IJGM.S326929","article-title":"Enteric-coated aspirin and the risk of gastrointestinal side effects: a systematic review.","volume":"14","author":"Kedir","year":"2021","journal-title":"Int J Gen Med"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/all.12260","article-title":"Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs.","volume":"68","author":"Kowalski","year":"2013","journal-title":"Allergy"},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/aje\/kwad168","article-title":"Compliance-adjusted estimates of aspirin effects among older persons in the ASPREE randomized trial.","volume":"192","author":"Smith","year":"2023","journal-title":"Am J Epidemiol"},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"107231","DOI":"10.1016\/j.cct.2023.107231","article-title":"Health characteristics and aspirin use in participants at the baseline of the ASPirin in reducing events in the elderly \u2013 eXTension (ASPREE-XT) observational study.","volume":"130","author":"Ernst","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archinternmed.2011.628","article-title":"Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.","volume":"172","author":"Seshasai","year":"2012","journal-title":"Arch Intern Med"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.amjmed.2011.01.018","article-title":"Effect of aspirin on mortality in the primary prevention of cardiovascular disease.","volume":"124","author":"Raju","year":"2011","journal-title":"Am J Med"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/M15-2113","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. preventive services task force.","volume":"164","author":"Guirguis-Blake","year":"2016","journal-title":"Ann Intern Med"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"R23-20261002","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.amjcard.2011.02.325","article-title":"Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.","volume":"107","author":"Bartolucci","year":"2011","journal-title":"Am J Cardiol"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/eurjpc\/zwab132","article-title":"Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.","volume":"28","author":"Pallikadavath","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"R25-20261002","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.xkme.2022.100547","article-title":"Aspirin for primary and secondary prevention of mortality, cardiovascular disease, and kidney failure in the Chronic Renal Insufficiency Cohort (CRIC) study.","volume":"4","author":"Taliercio","year":"2022","journal-title":"Kidney Med"},{"key":"R26-20261002","doi-asserted-by":"crossref","DOI":"10.1101\/2023.07.18.23292848","article-title":"The persistent underrepresentation of patients with chronic kidney disease in cardiovascular trials: a systematic review and evidence map of exclusion and outcomes.","author":"Colombijn","year":"2023","journal-title":"Cardiovasc Med"},{"key":"R27-20261002","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2022.09.023","article-title":"Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.","volume":"103","author":"Mann","year":"2023","journal-title":"Kidney Int"},{"key":"R28-20261002","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/jch.14091","article-title":"Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: a post hoc analysis.","volume":"23","author":"Desai","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R29-20261002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER study).","volume":"32","author":"Goicoechea","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"R30-20261002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2016.06.013","article-title":"Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: a meta-analysis.","volume":"251","author":"Major","year":"2016","journal-title":"Atherosclerosis"},{"key":"R31-20261002","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.ajkd.2016.01.019","article-title":"Aspirin use and incident cardiovascular disease, kidney failure, and death in stable kidney transplant recipients: a post hoc analysis of the folic acid for vascular outcome reduction in transplantation (FAVORIT) trial.","volume":"68","author":"Dad","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R32-20261002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/6139253","article-title":"Pros and cons of aspirin prophylaxis for prevention of cardiovascular events in kidney transplantation and review of evidence.","volume":"2019","author":"Khalil","year":"2019","journal-title":"Adv Prev Med"},{"key":"R33-20261002","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"key":"R34-20261002","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40256-018-0313-0","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: subanalysis of a randomized clinical trial (JPPP-70).","volume":"19","author":"Sugawara","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"R35-20261002","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"R36-20261002","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"R37-20261002","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1532-5415.1994.tb06864.x","article-title":"The PACE Pilot Study: 12-month results and implications for future primary prevention trials in the elderly.","volume":"42","author":"Silagy","year":"1994","journal-title":"J Am Geriatr Soc"},{"key":"R38-20261002","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"R39-20261002","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/eurheartj\/ehr423","article-title":"Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.","volume":"32","author":"Dorresteijn","year":"2011","journal-title":"Eur Heart J"},{"key":"R40-20261002","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJM198804073181413","article-title":"The Steering Committee of the Physicians\u2019 Health Study Research Group. The Physicians\u2019 Health Study: aspirin for the primary prevention of myocardial infarction.","volume":"318","year":"1988","journal-title":"N Engl J Med"},{"key":"R41-20261002","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archinte.160.7.921","article-title":"Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians\u2019 health study.","volume":"160","author":"Cook","year":"2000","journal-title":"Arch Intern Med"},{"key":"R42-20261002","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1001\/archinte.1994.00420230032005","article-title":"Adherence to aspirin in the prevention of myocardial infarction: the physicians\u2019 health study.","volume":"154","author":"Glynn","year":"1994","journal-title":"Arch Intern Med"},{"key":"R43-20261002","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/aje\/155.11.1045","article-title":"Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the physicians\u2019 health study.","volume":"155","author":"Cook","year":"2002","journal-title":"Am J Epidemiol"},{"key":"R44-20261002","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"R45-20261002","article-title":"Antiplatelet agents and anticoagulants for hypertension.","author":"Shantsila","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"R46-20261002","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus.","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"R47-20261002","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial.","volume":"135","author":"Saito","year":"2017","journal-title":"Circulation"},{"key":"R48-20261002","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1253\/circj.CJ-13-0307","article-title":"Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk.","volume":"77","author":"Okada","year":"2013","journal-title":"Circ J"},{"key":"R49-20261002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2337\/dc10-2451","article-title":"Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management.","volume":"34","author":"Okada","year":"2011","journal-title":"Diabetes Care"},{"key":"R50-20261002","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"R51-20261002","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients.","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"R52-20261002","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/dme.13133","article-title":"Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.","volume":"34","author":"Kunutsor","year":"2017","journal-title":"Diabet Med"},{"key":"R53-20261002","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00592-014-0623-x","article-title":"Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study.","volume":"52","author":"Sasso","year":"2015","journal-title":"Acta Diabetol"},{"key":"R54-20261002","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/key105","article-title":"The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION trial.","volume":"57","author":"Solomon","year":"2018","journal-title":"Rheumatology"},{"key":"R55-20261002","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3899\/jrheum.160930","article-title":"Primary prevention of myocardial infarction in rheumatoid arthritis using aspirin: a case-crossover study and a propensity score\u2013matched cohort study.","volume":"44","author":"Dur\u00e1n","year":"2017","journal-title":"J Rheumatol"},{"key":"R56-20261002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/2748035","article-title":"Low-dose aspirin as primary prophylaxis for cardiovascular events in rheumatoid arthritis: an Italian multicentre retrospective study.","volume":"2019","author":"Iacono","year":"2019","journal-title":"Cardiol Res Pract"},{"key":"R57-20261002","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes.","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6 Supplement","key":"R59-20261002","first-page":"S41","article-title":"Primary prevention of CVD with aspirin: benefits vs risks.","volume":"70","author":"Weisman","year":"2021","journal-title":"J Fam Pract"},{"key":"R60-20261002","doi-asserted-by":"crossref","first-page":"e0160046","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies.","volume":"11","author":"Garc\u00eda Rodr\u00edguez","year":"2016","journal-title":"PLoS One"},{"key":"R61-20261002","doi-asserted-by":"crossref","first-page":"1099810","DOI":"10.3389\/fphar.2023.1099810","article-title":"Low- or high-dose preventive aspirin use and risk of death from all-cause, cardiovascular disease, and cancer: a nationally representative cohort study.","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"R62-20261002","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.","volume":"324","author":"Collaboration","year":"2002","journal-title":"BMJ"},{"key":"R63-20261002","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement.","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"R64-20261002","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jama.2022.3385","article-title":"Aspirin use to prevent cardiovascular disease and colorectal cancer: updated modeling study for the US preventive services task force.","volume":"327","author":"Dehmer","year":"2022","journal-title":"JAMA"},{"key":"R65-20261002","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines.","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"R66-20261002","doi-asserted-by":"crossref","first-page":"100579","DOI":"10.1016\/j.ajpc.2023.100579","article-title":"Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)\u2014a review of the evidence.","volume":"15","author":"Sukkari","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"R67-20261002","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/ATVBAHA.122.318020","article-title":"Aspirin for the primary prevention of cardiovascular disease: time for a platelet-guided approach.","volume":"42","author":"Cofer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R68-20261002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/7786174","article-title":"Long-term adherence and persistence to low-dose aspirin for the prevention of cardiovascular disease: a population-based cohort study.","volume":"2022","author":"Vora","year":"2022","journal-title":"Int J Clin Pract"},{"key":"R69-20261002","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/11318440-000000000-00000","article-title":"Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation.","volume":"10","author":"Herlitz","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"R70-20261002","doi-asserted-by":"crossref","first-page":"d4094","DOI":"10.1136\/bmj.d4094","article-title":"Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care.","volume":"343","author":"Garcia Rodriguez","year":"2011","journal-title":"BMJ"},{"key":"R71-20261002","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ahj.2012.01.019","article-title":"Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial.","volume":"163","author":"Calvert","year":"2012","journal-title":"Am Heart J"},{"key":"R73-20261002","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/jama.2018.19271","article-title":"Interventions to improve medication adherence: a review.","volume":"320","author":"Kini","year":"2018","journal-title":"JAMA"},{"key":"R74-20261002","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11883-016-0630-1","article-title":"Aspirin use in women: current perspectives and future directions.","volume":"18","author":"Sarma","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"R75-20261002","first-page":"620","article-title":"Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke.","volume":"15","author":"Brown","year":"2005","journal-title":"Ethn Dis"},{"key":"R76-20261002","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3122\/jabfm.2021.01.200322","article-title":"Low-dose aspirin use among African American older adults.","volume":"34","author":"Bazargan","year":"2021","journal-title":"J Am Board Fam Med"},{"key":"R77-20261002","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1941875210395776","article-title":"Aspirin resistance.","volume":"1","author":"Schwartz","year":"2011","journal-title":"Neurohospitalist"},{"key":"R78-20261002","doi-asserted-by":"crossref","first-page":"11317","DOI":"10.3390\/ijms231911317","article-title":"Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy.","volume":"23","author":"Khan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R79-20261002","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.794417","article-title":"Mechanism of improving aspirin resistance: blood-activating herbs combined with aspirin in treating atherosclerotic cardiovascular diseases.","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"key":"R80-20261002","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/14622416.8.6.577","article-title":"Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.","volume":"8","author":"Li","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R81-20261002","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2008.03183.x","article-title":"Pharmacogenetics of aspirin resistance: a comprehensive systematic review.","volume":"66","author":"Goodman","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R82-20261002","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.2174\/138161212803251907","article-title":"Pharmacogenetics of the antiplatelet effect of aspirin.","volume":"18","author":"Wurtz","year":"2012","journal-title":"Curr Pharm Des"},{"key":"R83-20261002","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s10038-020-0818-7","article-title":"Personalized medicine for cardiovascular diseases.","volume":"66","author":"Tada","year":"2021","journal-title":"J Hum Genet"},{"key":"R84-20261002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13643-015-0078-3","article-title":"Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review.","volume":"4","author":"Bem","year":"2015","journal-title":"Syst Rev"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:01Z","timestamp":1790913661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000722","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}